DanCann Pharma A/S publishes Q4-2022 report

Rhea-AI Summary

DanCann Pharma A/S (OTCQB: DCPXF) announced its Q4 2022 financial report, revealing net sales of DKK 5.707 million, a significant increase from DKK 874,000 in Q4 2021. The operating profit (EBIT) was reported at DKK -17.587 million, worsening from DKK -14.508 million year-over-year. The result per share was DKK -0.25, improving from DKK -0.52 in the previous year. The equity ratio stood at 0.84, reflecting a robust financial position. The total number of shares at year-end was 65.014 million, compared to 28.468 million in 2021. The report emphasizes a favorable growth trajectory despite ongoing challenges.

Positive

• Net sales increased significantly from DKK 874,000 in Q4 2021 to DKK 5.707 million in Q4 2022.
• Result per share improved from DKK -0.52 in 2021 to DKK -0.25 in 2022.
• Equity ratio increased to 0.84, indicating strong financial stability.

Negative

• Operating profit (EBIT) worsened from DKK -14.508 million in Q4 2021 to DKK -17.587 million in Q4 2022.

COPENHAGEN, Denmark, Feb. 28, 2023 /PRNewswire/ -- DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the fourth quarter of 2022. The Q4-2022 report is available as an attached document to this press release and at www.dancann.com.

SUMMARY: GROUP KEY FIGURES Q4 2022

KDKK	01/01/22 - 31/12/22	01/01/21 - 31/12/21	01/10/22 - 31/12/22	01/10/21 - 31/12/21
Net sales	5.707	874	2.101	874
Operating profit (EBIT)	- 17.587	- 14.508	- 5.513	- 4.718
Result per share (DKK)	-0,25	-0,52	-0,17	-0,12
Equity ratio	0,84	0,78	0,78	0,79

Number of shares on 31.12.2022 = 65.014.639 (28.468.289)

Result per share = Result for the period / weighted average number of shares

Equity ratio = Equity / Total assets

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.

The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (OTCQB: DCPXF).

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO 
Phone: +45 2963 6920
E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

The following files are available for download:

https://mb.cision.com/Main/19875/3724532/1879607.pdf	DanCann Pharma AS publishes Q4-2022 report
https://mb.cision.com/Public/19875/3724532/9367d7f02380d352.pdf	DCP Q4 2022

 

View original content:https://www.prnewswire.com/news-releases/dancann-pharma-as-publishes-q4-2022-report-301757548.html

SOURCE DanCann Pharma

FAQ

What were DanCann Pharma's net sales for Q4 2022?

DanCann Pharma's net sales for Q4 2022 were DKK 5.707 million.

How much was DanCann Pharma's operating profit in Q4 2022?

The operating profit (EBIT) for DanCann Pharma in Q4 2022 was DKK -17.587 million.

What is the result per share for DanCann Pharma for 2022?

The result per share for DanCann Pharma in 2022 was DKK -0.25.

What is DanCann Pharma's equity ratio as of Q4 2022?

DanCann Pharma's equity ratio as of Q4 2022 was 0.84.

How many shares outstanding does DanCann Pharma have as of December 31, 2022?

As of December 31, 2022, DanCann Pharma had 65.014 million shares outstanding.